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CAD = coronary artery disease  
HTN = hypertension 
DM = diabetes mellitus 
DL = dyslipidemia 
MetS = metabolic syndrome 
MDCT = multi-detector row computed tomography  
PMMI = psoas major muscle index  
VFAI = visceral fat area index 
SFAI = subcutaneous fat area index 
BMI = body mass index  
SBP = systolic blood pressure  
DBP = diastolic blood pressure 
TC = total cholesterol 
TG = triglyceride 
HDL-C = high-density lipoprotein cholesterol 
LDL-C = low-density lipoprotein cholesterol 
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UA = uric acid 
FBG = fasting blood glucose  
HbA1c = hemoglobin A1c 
MI = myocardial infarction  
ROC = a receiver-operating characteristic curve 
ARB = angiotensin II receptor blocker 
ACEI = angiotensin-converting enzyme inhibitor  
CCB = calcium channel blocker 
SU = sulfonylurea 
DPP-4I = dipeptidyl peptidase-4 inhibitor 
VD = the number of significantly stenosed coronary vessels  





The associations between the presence and severity of coronary artery disease (CAD) 
and measurements of the psoas major muscle (PMM) as assessed by multidetector row 
coronary computed tomography angiography (MDCT) are not known.  
We enrolled 793 patients who were clinically suspected to have CAD or had at least one 
cardiac risk factor and had undergone MDCT. The number of significantly stenosed 
coronary vessels (VD) and measurements of the PMM index (PMMI) were determined 
using MDCT.  
PMMI in the CAD group was significantly lower than that in the non-CAD group in 
males, but not females. In addition, the levels of PMMI tended to increase as the 
number of VD decreased in males. When male patients were divided into two groups 
according to median value of age, i.e., relatively younger (53.4±9.2 years) and older 
(72.6±5.7 years) groups, the presence of CAD was independently associated with 
PMMI in the younger group by a multiple logistic regression analysis. The cut-off level 
of PMMI that gave the greatest sensitivity and specificity for the diagnosis of CAD in 




 (sensitivity 0.441, specificity 0.752).  
In conclusion, PMMI may be an imaging marker for evaluating the presence and/or 
severity of CAD in males, and particularly in the non-elderly. 
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Coronary artery disease (CAD) is mainly caused by arteriosclerosis. There are various 
risk factors for the onset and/or progression of CAD, such as hypertension (HTN), 
diabetes mellitus (DM), dyslipidemia (DL), and metabolic syndrome (MetS). Many 
studies have shown that visceral fat has a detrimental effect on metabolism and the risk 
of CAD [1-3]. The best tool for estimating visceral fat is multi-detector row computed 
tomography (MDCT). MDCT has become more widely available in many general 
hospitals and enables the accurate non-invasive assessment of coronary artery stenosis 
[4], calcification [5], and plaque [6]. Aging is also a risk factor for CAD [7], and the 
proportion of multi-vessel CAD has been reported to increase with aging [8]. In 
addition, aging has been reported to be associated with sarcopenia [9]. Sarcopenia is a 
progressive and generalized skeletal muscle condition that is associated with an 
increased likelihood of adverse outcomes, including falls, fractures, physical disability 
and mortality. Diagnostic criteria for sarcopenia include low muscle strength, low 
muscle quantity or quality, and low physical performance [10]. Muscle mass can be 
measured by bioelectrical impedance analysis or dual-energy X-ray absorptiometry. 
Recently, a method for measuring muscle mass by CT has been reported. The 
quantification of muscle mass by CT is associated with the prognosis of cancer [11, 12] 
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and liver cirrhosis [13]. It has also been considered that a psoas major muscle index 
(PMMI) may be useful for evaluating the skeletal muscle mass for the whole body [14]. 
The PMM is measured using image-viewing software by tracing the PMM at the lumbar 
L3 cross-section by CT [13]. Although it has been reported that there is a relation 
between atherosclerosis and low muscle mass [15, 16], the association between the 
presence and/or severity of CAD and PMMI is unclear.  
Since the elderly patients have lower PMM associated with sarcopenia, and since 
aging is a risk factor for CAD, we hypothesized that PMM may be an imaging marker 
for evaluating the presence and/or severity of CAD. Therefore, we determined the levels 
of PMMI quantified using MDCT and image-viewing software, and investigated the 




Seven hundred ninety-three consecutive subjects who were clinically suspected of 
having CAD or who had at least one cardiac risk factor were enrolled in this 
cross-sectional study. All subjects underwent MDCT coronary angiography between 
April 2012 and August 2017. Patients with creatinine >2.0 mg/dl or contrast-induced 
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allergy did not undergo MDCT. The protocol in this study was approved by the ethics 
committee of Fukuoka University Hospital, and all subjects gave their written informed 
consent to participate. 
 
Evaluation of coronary stenosis using MDCT 
We evaluated coronary stenosis using MDCT as previously described [17]. Two 
hundred seventy-two patients who underwent MDCT were scanned by 64-MDCT on an 
Aquilion 64 (TOSHIBA, Tokyo, Japan), and five hundred twenty-one of these were 
scanned by 320-MDCT on an Aquilion ONE ViSION (TOSHIBA, Tokyo, Japan). The 
use of beta-blocker and nitroglycerin before scanning was left to the physician’s 
discretion. In the first MDCT, a 70-mL bolus of contrast medium (Omnipaque, 350 mg 
iodine/mL; Daiichi Sankyo Co., Ltd., Tokyo, Japan) was injected at a flow rate of 3.6 
mL/sec, followed by 35 mL contrast agent and 30 mL saline solution, each at 1.8 
mL/sec, with a dual injector. In the second MDCT, 21.5 mgI/kg/sec contrast medium 
(Iopamiron, 370 mg iodine/mL; Bayer Yakuhin. Ltd, Osaka, Japan) equivalent to the 
patient’s body weight × 0.7 mL was injected over 10 sec, followed by 35 mL contrast 
agent and 30 mL saline solution, each at 1.8 mL/sec, with a dual injector. 
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The region of interest was placed within the ascending aorta, and the scan was started 
when the CT density reached 100 Hounsfield Units higher than the baseline CT density. 
The scan was performed between the tracheal bifurcation and diaphragm with the 
following parameters: 64-MDCT-collimation width 0.5 mm, rotation speed 0.4 
sec/rotation, tube voltage 135 kV, and effective tube current 360 mA; 
320-MDCT-collimation width 0.5 mm, rotation speed 0.275 sec/rotation, tube voltage 
120 kV, and auto tube current. 
Overall, 15 coronary artery segments were assessed in all patients.  Narrowing of 
the normal contrast-enhanced lumen to ≥ 50 % that could be identified in multiplanar 
reconstructions or cross-sectional images was defined as significant stenosis in CAD. In 
addition, in all patients, the atherosclerotic severity of coronary artery disease was 
assessed in terms of the Gensini score [18, 19]. 
 
Measurement of psoas major muscle 
CT scans were performed by MDCT and Ziostation workstation (Ziosoft Inc., Tokyo. 
Japan). When we performed CT imaging of the coronary artery and measured visceral 
fat area (VFA) and subcutaneous fat area (SFA) at the umbilical level (L4 to L5), we 
measured PMM simultaneously at the umbilical level. PMM was quantified using 
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MDCT and image-viewing software (Osirix 9.0, Geneva, Switzerland) (Figure 1) [20, 









Evaluation of risk factors for CAD 
Body mass index (BMI), systolic blood pressure (SBP), diastolic BP (DBP), serum 
levels of total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol 
(HDL-C), and low-density lipoprotein cholesterol (LDL-C), uric acid (UA), fasting 
blood glucose (FBG), hemoglobin A1c (HbA1c), smoking status (current versus 
nonsmokers), family history [myocardial infarction (MI), angina pectoris or sudden 
death] and medication use were collected as risk factors in all patients. 
BMI was calculated as weight (kg)/height (m)
2
. BP was determined as the mean of 
two measurements obtained in an office setting by the conventional cuff method using a 
mercury sphygmomanometer after at least 5 minutes of rest. All of the blood samples 
were drawn in the morning after the patients had fasted overnight. The characteristics of 
patients were obtained from medical records with regard to history of HTN, DL, DM 
and history of smoking. Patients who had a current SBP/DBP ≥ 140/90mmHg or who 
were receiving antihypertensive therapy were considered to have HTN. Patients with 
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LDL-C ≥ 140 mg/dl, TG ≥ 150 mg/dl, and/or HDL-C < 40 mg/dl or who were receiving 
lipid-lowering therapy were considered to have DL [22]. DM was defined using the 




A statistical analysis was performed using Excel 2016 (SSRI, Tokyo, Japan), the Stat 
View statistical software package (Stat View 5; SAS Institute Inc., Cary, NC, USA) and 
EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan). Continuous 
variables are shown as the mean ± standard deviation. Categorical and continuous 
variables were compared between the groups by a chi-square analysis and t-test, 
respectively. A multivariate analysis was performed by a logistic regression analysis for 
independent variables that were related to the presence or absence of CAD. A 
receiver-operating characteristic (ROC) curve analysis was used to determine the cut-off 
levels of PMMI to distinguish between the presence and absence of CAD at the highest 





Patient characteristics in all patients and the non-CAD and CAD groups 
Table 1 shows the characteristics of the 793 patients, who consisted of 379 (48.0 %) 
males and 414 (52.0 %) females. The frequencies of HTN, DM and DL in all patients 
were 64.0 %, 19.8 % and 55.5 %, respectively. The mean age was 65.5 ± 11.8 years and 
BMI was 23.8 ± 3.6 kg/m
2
. 
There were several significant differences in patient characteristics between the 
non-CAD and CAD groups. The CAD group showed a significantly higher age, % 
males, % Smoking, % HTN, SBP, DBP, % DL, % DM, FBG, HbA1c, VFAI, and 
Gensini score, and significantly lower levels of HDL-C than the non-CAD group. The 
percentages of the use of angiotensin II receptor blocker (ARB)/angiotensin-converting 
enzyme inhibitor (ACEI), calcium channel blocker (CCB) and statin in all patients were 
36.4 %, 38.0 % and 31.7 %, respectively. There were significant differences in 
medications between the non-CAD and CAD groups. The CAD group showed 
significantly higher percentages of the use of ARB/ACEI, CCB, -blocker, statin, 
sulfonylurea (SU), and dipeptidyl peptidase-4 inhibitor (DPP-4I) than the non-CAD 
group. 
 
Patient characteristics in the non-CAD and CAD groups in males and females. 
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Table 2 shows the differences in patient characteristics between the non-CAD and CAD 
groups in males and females. The CAD group showed a significantly higher age, % 
HTN, SBP, HbA1c, VFAI and Gensini score, and significantly lower levels of PMMI 
and HDL-C than the non-CAD group in males. The CAD group also showed 
significantly higher percentages of the use of statin than the non-CAD group in males. 
Among females, the CAD group showed a significantly higher age, % HTN, SBP, % 
DL, % DM, HbA1c, FGB and Gensini score and a significantly lower level of HDL-C 
than the non-CAD group. The CAD group also showed significantly higher percentages 
of the use of ARB/ACEI, CCB, -blocker, statin, SU, and DPP-4I than the non-CAD 
group in females. 
 
Measurements of PMMI in the non-CAD and CAD groups 
As shown in Tables 1 and 2, we analyzed whether there were differences in PMMI 
between the non-CAD and CAD groups in all patients, males and females. Although 
there was no difference in PMMI between the non-CAD and CAD groups in all patients, 





Association between PMMI and the number of significantly stenosed coronary 
vessels (VD) 
The subjects were divided into 4 groups according to the number of significantly 
stenosed coronary vessels (0, 1, 2 and 3VD groups) (Figure 2). PMMI tended to 
increase as the number of VD increased in males (p for trend < 0.001), but not females. 
Males with multi-VD (2 and 3 VD) had significantly lower levels of PMMI than those 
with 0 VD. 
 
Associations between PMMI and age in all patients, males and females 
PMMI was negatively associated with age in all patients, males and females (Figure 3). 
The association between PMMI and age in males was relatively high (r=-0.437), 
whereas that in females was very low (r=-0.136). 
Further, all patients were divided into two groups according to median value of age; 
relatively younger (56.4±9.2 years) and older (74.6±5.3 years) groups. Next, the 
patients of each gender were divided into two groups according to age; relatively 
younger (53.4±9.2 years) and older (72.6±5.7 years) groups in males, and relatively 
younger (59.5±8.7 years) and older (76.0±4.9 years) groups in females. Associations 
between age and PMMI in the younger and older groups were determined. Among 
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males, PMMI in the younger (r=-0.170, p=0.019) and older (r=-0.209, p=0.004) groups 
were significantly negatively associated with age, but the r values were relatively low. 
 
Predictors of the presence of CAD in all patients, males and females 
Since PMMI in the CAD group was significantly higher than that in the non-CAD 
group in males (Table 2), we sought to identify predictors of the presence of CAD in 
males using independent variables by a logistic regression analysis in Tables 3 (males) 
and 4 (females). We selected conventional coronary risk factors (age, BMI or VFAI, 
HTN, DL, DM and smoking) and PMMI (Table 3a-c). In all males, the presence of 
CAD was independently associated with age (p<0.0001) (Table 3a). We also sought to 
identify predictors of the presence of CAD in younger (Table 3b) and older (Table 3c) 
groups in males separately using independent variables, including conventional 
coronary risk factors and PMMI, by a logistic regression analysis. Because PMMI in 




) tended to be lower than that in males 













 in patients 
without CAD, p=0.182). The presence of CAD in younger males was associated with 
PMMI (p=0.038) in addition to age (p<0.001) and BMI (p=0.042), whereas there was 
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no association between the presence of CAD and PMMI in older males. When we 
performed a logistic regression analysis using VFAI instead of BMI as an independent 
variable (Table 3d-f), the presence of CAD in younger males was not associated with 
VFAI and PMMI. There were differences in predictors of CAD in younger males 
between the results by a logistic regression analysis using BMI (Table 3b) and the 
results using VFAI (Table 3e) probably because VFAI was positively associated with 
PMMI (r=0.283, p<0.0001). 
In all females, a logistic regression analysis using BMI as an independent variable 
indicated that the presence of CAD was associated with age (p<0.001), HTN (p=0.003) 
and DM (p=0.007) (Table 4a). The presence of CAD in younger and older females were 
associated with DM (p=0.006) and HTN (p=0.017), respectively (Table 4bc), whereas 
there was no association between the presence of CAD and PMMI in all females, 
younger and older females (Table 4). When we performed a logistic regression analysis 
using VFAI instead of BMI as an independent variable (Table 4d), the presence of CAD 
was associated with age, HTN and DM. Predictors in the presence of CAD by a logistic 
regression analysis using VFAI as an independent variable were similar to those using 




Cut-off values of PMMI and VFAI in younger males for the diagnosis of CAD  
We performed a ROC curve analysis to determine PMMI in younger males related to 
the presence of CAD (Figure 4a). The ROC curve analysis showed that the 
area-under-the-curve (AUC) of PMMI was 0.582 (sensitivity 0.441, specificity 0.752). 
The cut-off level of PMMI that gave the greatest sensitivity and specificity for the 





  Since there was a significant difference in VFAI between non-CAD and CAD groups 
in males as shown in Table 2, we also performed a ROC curve analysis to determine 
VFAI in younger males related to the presence of CAD (Figure 4b). The AUC and 





respectively. The AUC in VFAI was comparable to that in PMMI.  
 
Discussion 
In the present study, we investigated the associations between PMMI and the presence 
and severity of CAD as assessed by MDCT. PMMI in males, but not females, was 
associated with the presence and severity of CAD. Unexpectedly, in particular, the 
presence of CAD was independently associated with PMMI in non-elderly males, but 
not elderly males, by a multivariate logistic regression analysis. 
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The main finding in this study was that PMMI in males, but not females, was 
associated with the presence and severity of CAD. There may be some mechanisms 
why there was a gender difference. Although a reduction in muscle mass has been 
reported to be associated with atherosclerosis, this association was recognized only in 
males [16]. Testosterone increases muscle mass by increasing muscle protein synthesis 
[25]. In addition, low testosterone levels in males have been associated with an increased 
atherosclerosis burden and increased risk of cardiovascular events [26, 27]. 
Atherosclerosis induced by testosterone deficiency in male mice was T-cell-dependent 
[28]. Testosterone may be play a role in both muscle mass reduction and the mechanism 
of arteriosclerosis. Although we did not measure testosterone in this study, testosterone 
is known to decrease with age in males, but not females [29]. We found that the 
association between PMMI and age in males was relatively high (r=0.437), whereas that 
in females was very low (r=0.136). This suggests that testosterone might contribute to 
the association between muscle mass and CAD in males. 
Next, the presence of CAD was independently associated with PMMI in younger 
males, but not older males, although the presence of CAD was most strongly associated 
with age by a multivariate logistic regression analysis in all males. This may be because 
the risk of CAD increased when patients in the younger group have a small muscle mass, 
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probably due to less testosterone secretion. Aging generally exacerbates sarcopenia, i.e., 
muscle mass decreases with aging [30]. The presence of CAD was not associated with 
PMMI in older males because this change occurs naturally in the elderly. Thus, loss of 
muscle mass in non-elderly people may be a risk related to the onset of CAD. 
  The ROC curve analysis showed that the AUC of PMMI was 0.582 (sensitivity 0.441, 
specificity 0.752). VFAI is also associated with the presence of CAD. Since there was a 
significant difference in VFAI between non-CAD and CAD groups in males as shown in 
Table 2, we also performed a ROC curve analysis to determine VFAI in younger males 
related to the presence of CAD. The AUC and cut-off level of VFAI were 0.590 




, respectively. The AUC in VFAI 
was comparable to that in PMMI.  





. A clear standard range of PMMI has not been determined. Hamaguchi et al. 





 for females in Japanese populations [14]. Although the average values of PMMI 













) in this study were similar to those in Japanese populations, most of 
the subjects in those populations were less than 65 years old, and thus much younger 
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than our subjects (average age 65.5 years). In addition, we measured PMM at the 
umbilical level (L4 to L5), whereas they did it at L3 level. The standard range of PMM 
in large populations should be determined. 
Many studies suggested microRNA (miR) as strong circulating biomarkers with high 
diagnostic as well as prognostic power in cardiovascular diseases [31]. A decrease in the 
levels of the miR-15a expression in basal conditions is observed in Type 1 DM patients 
[32]. In addition, endothelial miR-16 is remarkably upregulated after vascular injury in 
the presences of peripheral muscle ischemia and exerts a negative effect on endothelial 
repair through the inhibition of RhoGDIα and nitric oxide production [33]. Thus, the 
ischemia affects negative carotid remodeling increasing neointima formation after 
injury. We should analyze the association between the psoas muscle or miR and the 
presence and severity of CAD in near future. 
  
Study limitations 
This study has several important limitations. First, this study was cross-sectional and 
did not analyze clinical outcomes over the long term. Second, a considerable amount of 
time was needed to measure PMMI in each patient; the development of automated 
analytical software would be helpful. Third, PMM is involved in various physical 
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activities of daily living like running, dancing, sitting, and walking. Although regular 
physical activity decreases the incidence of CAD [34], we did not determined the 




PMMI may be an imaging marker for evaluating the presence and severity of CAD in 
males, and particularly in the non-elderly. 
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Figure 1.  
Measurement of the psoas major muscle index (PMMI). 
 
Figure 2. 
Psoas major muscle index (PMMI) in all patients (a), males (b) and females (c) in the 0-  
VD, 1-VD, 2-VD and 3-VD groups.  
VD, the number of significantly stenosed coronary vessels. **p<0.01; *p<0.05.  
 
Figure 3.  
Association between the psoas major muscle index (PMMI) and age in all patients, 
males and females. 
 
Figure 4.  
Cut-off values of psoas major muscle index (PMMI) (a) and measured visceral fat area 










non-CAD group vs. 
CAD group 
  (n=793) (n=391) (n=402) p value 
Age, yrs 66±12 62±13 69±10 <0.0001 
Gender (male), % 48 41 55 0.0001 
Family history, % 23 23 23 0.963 
Smoking, % 34 31 38 0.029 
BMI, kg/m
2
 23.8±3.6 23.8±3.5 23.8±3.7 0.896 
HTN, % 64 56 72 <0.0001 
 SBP, mmHg 136±19 132±17 139±21 <0.0001 
 DBP, mmHg 78±13 77±13 79±13 0.016 
DL, % 56 51 60 0.015 
 TG, mg/dl 137±102 133±108 141±97 0.254 
 HDL-C, mg/dl 57±16 59±17 54±15 <0.0001 
 LDL-C, mg/dl 115±33 116±34 113±31 0.194 
DM, % 20 14 25 <0.0001 
 HbA1c, % 6.1±1.7 5.9±0.8 6.3±2.2 0.002 















 62±33 64±33 60±33 0.077 
Gensini score 11.2±15.2 2.8±3.8 19.4±17.6 <0.0001 
Medications 
     ARB/ACE-I, % 36 30 42 0.0005 
 CCB, % 38 31 45 0.0001 
 -blocker, % 9.0 5.6 12 0.001 
 DU, % 9.5 8.2 11 0.227 
 Statin, % 32 25 38 0.0001 
 Fibrate, % 1.0  1.0  1.0  0.969 
 Ezetimib, % 1.9 2.8 1.0  0.060 
 EPA, % 3.8 3.6 4.0  0.769 
 SU, % 7.6 5.1 10 0.014 
 -GI, % 2.3 1.5 3.0  0.171 
 Biguanide, % 6.3 4.9 7.7  0.099 
 Thiazolidine, %  2.8 2.8 2.7 0.948 
 DPP-4I, % 10 7.2 13 0.005 
 Insulin, % 3.0  2.8 3.2  0.730 
Continuous variables are expressed as mean ± SD. CAD, coronary artery disease; BMI, 
body mass index; HTN, hypertension; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; DL, dyslipidemia; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; 
LDL-C, low-density lipoprotein cholesterol; DM, diabetes mellitus; HbA1c, hemoglobin 
A1c; FBG, fasting blood glucose; PMMI, psoas major muscle index; VFAI, visceral fat 
area index; SFAI, subcutaneous fat area index; ARB, angiotensin II receptor blocker; 
ACE-I, angiotensin-converting enzyme inhibitor; CCB, calcium channel blocker; DU, 
diuretic; EPA, eicosapentaenoic acid; SU, sulfonylurea; -GI, -glucosidase inhibitor; 


































Age, yrs 59±14 66±10 <0.0001 
 
65±12 71±9 <0.0001 
Family history, % 20 18.7 0.756  
26 28 0.513 
Smoking, % 53 60.3 0.166 
 
15 12 0.279 
BMI, kg/m
2
 24.4±3.3 24.3±3.7 0.820 
 
23.4±3.7 23.3±3.7 0.727 
HTN, % 59 70 0.034 
 
53 75 <0.0001 
 SBP, mmHg 135±16 140±20 0.007 
 
130±18 139±21 <0.0001 
 DBP, mmHg 81±12 82±13 0.480 
 
74±13 76±13 0.158 
DL, % 50 58 0.123 
 
52 62 0.046 
 TG, mg/dl 156±145 153±118 0.809 
 
117±68 127±61 0.102 
 HDL-C, mg/dl 55±15 50±12 0.0008 
 
63±17 58±17 0.009 
 LDL-C, mg/dl 112±34 111±31 0.848 
 
119±34 115±32 0.244 
DM, % 21 29 0.098 
 
9.1 21 <0.001 
 HbA1c, % 5.9±1.0 6.4±2.8 0.038 
 
5.9±0. 7 6.0±0.7 0.005 
 FBG, mg/dl 109±33 113±30 0.237 
 










 44±22 49±23 0.034 
 





 46±20 47±24 0.840 
 
77±34 76±36 0.866 
Gensini score 3.3±4.2 22.5±20.7 <0.0001 
 
2.3±3.4 15.7±11.9 <0.0001 
Medications 
       
 ARB/ACE-I, % 33 42 0.060 
 
29  43 0.004 
 CCB, % 30 37 0.157 
 
32  54 <0.0001 
 -blocker, % 6.3 12 0.066 
 
5.2 13 0.007 
 DU, % 7.5 10  0.393 
 
8.7 12 0.342 
 Statin, % 24 34 0.048 
 
26 43 <0.001 
 Fibrate, % 1.3 1.4  0.920 
 
0.9 0.5 0.744 
 Ezetimib, % 2.5 0.9  0.223 
 
3.0 1.1 0.180 
 EPA, % 1.3 4.1  0.102 
 
5.2  3.8 0.510 
 SU, % 8.1 12 0.263 
 
3.0  7.7  0.043 
 -GI, % 2.5 4.1  0.397 
 
0.9  1.6 0.475 
 Biguanide, % 6.9 11 0.133 
 
3.5  3.3 0.918 
 Thiazolidine, %  3.1 2.7 0.826 
 
2.6  2.7 0.933 
 DPP-4I, % 10 15  0.183 
 
5.2  12 0.019 
 Insulin, % 5.0 2.3 0.152   1.3  4.4 0.054 
Continuous variables are expressed as mean ± SD. CAD, coronary artery disease; BMI, body mass 
index; HTN, hypertension; SBP, systolic blood pressure; DBP, diastolic blood pressure; DL, dyslipidemia; 
TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low- density lipoprotein cholesterol; 
DM, diabetes mellitus; HbA1c, hemoglobin A1c; FBG, fasting blood glucose; PMMI, psoas major muscle 
index; VFAI, visceral fat area index; SFAI, subcutaneous fat area index; ARB, angiotensin II receptor 
blocker; ACE-I, angiotensin-converting enzyme inhibitor; CCB, calcium channel blocker; DU, diuretic; 





Table 3. Predictors in the presence of CAD in males. 
a.     Males (all)  Predictors including BMI in addition to 
PMMI 
 
d.     Males (all)  
Predictors including VFAI in 
addition to PMMI 
  OR（95%CI） p value     OR（95%CI） p value 
Age 1.063（1.039-1.087） <0.001 
 
Age 1.058（1.034-1.082） <0.001 
BMI 1.080（0.995-1.171） 0.061 
 
VFAI 1.009（0.998-1.021） 0.113  
HTN 1.026（0.635-1.658） 0.917 
 
HTN 1.032（0.636-1.675） 0.898  
DL 1.409（0.900-2.204） 0.133 
 
DL 1.308（0.833-2.055） 0.244  
DM 1.145（0.681-1.927） 0.609 
 
DM 1.219（0.723-2.057） 0.457  
Smoking 1.458（0.935-2.274） 0.095 
 
Smoking 1.385（0.887-2.162） 0.152  










Predictors including VFAI in 
addition to PMMI 
  OR（95%CI） p value     OR（95%CI） p value 
Age 1.072（1.026-1.120） <0.001 
 
Age 1.063（1.019-1.110） 0.005 
BMI 1.116（1.001-1.244） 0.042 
 
VFAI 1.010（0.993-1.028） 0.245  
HTN 1.466（0.742-2.897） 0.270  
 
HTN 1.507（0.760-2.985） 0.240  
DL 1.645（0.867-3.119） 0.126  
 
DL 1.456（0.762-2.782） 0.256  
DM 1.010（0.469-2.176） 0.980  
 
DM 1.216（0.566-2.614） 0.616  
Smoking 1.533（0.808-2.905） 0.189  
 
Smoking 1.403（0.739-2.665） 0.300  
PMMI 0.807（0.657-0.992） 0.038   PMMI 0.870（0.720-1.052） 0.151  
c. Males       
(Older groups) 
Predictors including BMI in addition to 
PMMI 
 
f. Males       
(Older groups) 
Predictors including VFAI in 
addition to PMMI 
  OR（95%CI） p value     OR（95%CI） p value 
Age 1.023（0.965-1.085） 0.448  
 
Age 1.022（0.964-1.084） 0.468  
BMI 1.009（0.876-1.162） 0.905  
 
VFAI 1.004（0.989-1.020） 0.590  
HTN 0.724（0.344-1.525） 0.390  
 
HTN 0.698（0.331-1.471） 0.344  
DL 1.060（0.551-2.039） 0.861  
 
DL 1.060（0.549-2.046） 0.863  
DM 1.092（0.527-2.260） 0.813  
 
DM 1.095（0.528-2.272） 0.808  
Smoking 1.296（0.682-2.464） 0.429  
 
Smoking 1.309（0.688-2.490） 0.412  
PMMI 1.147（0.875-1.504） 0.319    PMMI 1.141（0.895-1.454） 0.288  
PMMI, psoas major muscle index; BMI, body mass index; HTN, hypertension; DL, dyslipidemia; DM, diabetes 




Table 4. Predictors in the presence of CAD in females. 
a.     Females 
(all)  
Predictors including BMI in addition to 
PMMI 
 
d.     Females 
(all)  
Predictors including VFAI in 
addition to PMMI 
  OR（95%CI） p value     OR（95%CI） p value 
Age 1.061（1.036-1.087） <0.001 
 
Age 1.069（1.043-1.097） <0.001 
BMI 0.964（0.904-1.027） 0.259 
 
VFAI 0.997（0.986-1.007） 0.505  
HTN 1.997（1.260-3.164） 0.003 
 
HTN 1.760（1.098-2.822） 0.019 
DL 1.185（0.769-1.829） 0.442 
 
DL 1.237（0.790-1.936） 0.352  
DM 2.353（1.264-4.380） 0.007 
 
DM 2.288（1.211-4.321） 0.011 
Smoking 1.190（0.617-2.294） 0.603 
 
Smoking 1.221（0.623-2.396） 0.561  










Predictors including VFAI in 
addition to PMMI 
  OR（95%CI） p value     OR（95%CI） p value 
Age 1.033（0.986-1.082） 0.171  
 
Age 1.042（0.992-1.094） 0.099  
BMI 0.942（0.852-1.041） 0.239  
 
VFAI 0.999（0.983-1.015） 0.919  
HTN 1.676（0.847-3.316） 0.138  
 
HTN 1.365（0.680-2.740） 0.382  
DL 1.134（0.591-2.178） 0.705  
 
DL 1.160（0.593-2.268） 0.665  
DM 3.734（1.462-9.537） 0.006 
 
DM 3.082（1.230-7.726） 0.016 
Smoking 0.746（0.313-1.781） 0.510  
 
Smoking 0.775（0.315-1.909） 0.580  
PMMI 1.116（0.877-1.419） 0.373    PMMI 1.094（0.866-1.382） 0.450  
c. Females       
(Older groups) 
Predictors including BMI in addition to 
PMMI 
 
f. Females       
(Older groups) 
Predictors including VFAI in 
addition to PMMI 
  OR（95%CI） p value     OR（95%CI） p value 
Age 1.048（0.986-1.113） 0.135  
 
Age 1.056（0.992-1.124） 0.085 
BMI 0.972（0.890-1.062） 0.530  
 
VFAI 0.995（0.981-1.009） 0.471 
HTN 2.204（1.152-4.217） 0.017 
 
HTN 2.061（1.056-4.023） 0.034 
DL 1.327（0.729-2.414） 0.355  
 
DL 1.373（0.737-2.559） 0.318 
DM 1.672（0.718-3.895） 0.234  
 
DM 1.757（0.724-4.260） 0.213 
Smoking 3.310（0.854-12.832） 0.083  
 
Smoking 3.228（0.829-12.56） 0.091 
PMMI 0.897（0.696-1.156） 0.400    PMMI 0.914（0.716-1.165） 0.466 
PMMI, psoas major muscle index; BMI, body mass index; HTN, hypertension; DL, dyslipidemia; DM, diabetes 
mellitus; CAD, Coronary artery disease. Underlines are indicated p<0.05. 
 

























































Figure 2.  
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Age Age Age 
All All (younger groups) All (older groups) 







25 35 45 55 65 























b. VFAI       
 AUC 0.590 
